The present invention provides vacuolar-type (H+)-ATPase-inhibiting compounds, compositions thereof, and methods of using them to treat or prevent a condition treatable by the inhibition of a vacuolar-type (H+)-ATPase. The composition of the present invention comprises a compound of the present invention and a carrier. The method of the present invention includes administering a vacuolar-type (H+)-ATPase inhibiting-effective amount of a compound of the present invention. The compound of the present invention has formula (I) wherein R.sup.1 and R.sup.2 are H, saturated or unsaturated alkyl, aryl, R.sup.6CH.sub.2--, R.sup.6CO--, or R.sup.6SO.sub.2--, wherein R.sup.6 is H, saturated or unsaturated alkyl, or aryl; R.sup.3 is H, alkyl, aryl, an oxime, or an oxime methyl ether; the aromatic ring is unsubstituted or substituted; and Z is a contiguous linker comprising a chain of 0-10 atoms which, together with the five atoms beginning with the carbon of the aromatic ring in meta-relationship with OR.sup.1 and ending with the carbon directly attached to the alkyl oxygen of the lactone, integrally form a 5-17 membered ring; or a pharmaceutically acceptable salt, an ester, or a prodrug thereof.

 
Web www.patentalert.com

< Macrocycles for the treatment of cancer

> 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative

~ 00437